1-Palmitoylglycerophosphocholine | 15895-31-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1-Palmitoylglycerophosphocholine
• 英文别名: 2-[(3-hexadecanoyloxy-2-hydroxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
• CAS: 15895-31-5
• 化学式: C24H51NO7P+
• 分子量: 496.6
• InChiKey: ASWBNKHCZGQVJV-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  33
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Biomarkers for diagnosing multiple sclerosis, and methods thereof
  申请人：Phenomenome Discoveries Inc.

  公开号：EP2644588A2

  公开（公告）日：2013-10-02

  The present invention describes methods for the diagnosis and differential diagnosis of the different forms of multiple sclerosis. The methods measure the intensities of specific small molecules called metabolites in samples from patients with clinically diagnosed relapsing-remitting or primary-progressive forms of multiple sclerosis and compare these intensities to the intensities observed in a population of healthy individuals, thus identifying markers of multiple sclerosis. A method is also provided for the differential diagnosis of subjects afflicted with relapsing-remitting multiple sclerosis from secondary-progressive multiple sclerosis.

  本发明描述了诊断和鉴别诊断不同形式多发性硬化症的方法。这些方法测量临床诊断为复发-缓解型或原发性进展型多发性硬化症患者样本中被称为代谢物的特定小分子的强度，并将这些强度与在健康人群中观察到的强度进行比较，从而确定多发性硬化症的标记物。此外，还提供了一种方法，用于鉴别诊断复发缓解型多发性硬化症患者和继发性进展型多发性硬化症患者。
• BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF
  申请人：Phenomenome Discoveries Inc.

  公开号：EP3231789A1

  公开（公告）日：2017-10-18

  The present invention describes methods for the diagnosis and differential diagnosis of the different forms of multiple sclerosis. The methods measure the intensities of specific small molecules called metabolites in samples from patients with clinically diagnosed relapsing-remitting or primary-progressive forms of multiple sclerosis and compare these intensities to the intensities observed in a population of healthy individuals, thus identifying markers of multiple sclerosis. A method is also provided for the differential diagnosis of subjects afflicted with relapsing-remitting multiple sclerosis from secondary-progressive multiple sclerosis.

  本发明描述了诊断和鉴别诊断不同形式多发性硬化症的方法。这些方法测量临床诊断为复发-缓解型或原发性进展型多发性硬化症患者样本中被称为代谢物的特定小分子的强度，并将这些强度与在健康人群中观察到的强度进行比较，从而确定多发性硬化症的标记物。此外，还提供了一种方法，用于鉴别诊断复发缓解型多发性硬化症患者和继发性进展型多发性硬化症患者。
• PHOSPHOLIPID DERIVATIVES AND THEIR USE AS MEDICAMENTS
  申请人：Ustav molekularni genetiky AV CR, v.v.i.

  公开号：EP3606534B1

  公开（公告）日：2021-05-12
• BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER, AND METHODS THEREOF
  申请人：Ritchie Shawn

  公开号：US20090127454A1

  公开（公告）日：2009-05-21

  The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and/or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer.
• PROCESS
  申请人：Larsen Niels Erik

  公开号：US20100215803A1

  公开（公告）日：2010-08-26

  The use of a lipid acyltransferase in the manufacture of UHT milk for improving the stability, particularly the long term stability, and/or improving the perceptible sensory difference and/or improving smell and/or taste and/or for reducing the cholesterol content and/or for eliminating or reducing creaming of the UHT milk for reducing the cholesterol content in the UHT milk. A method of producing UHT milk, wherein method comprises admixing a lipid acyltransferase and milk (including a step of processing the milk to make it a UHT milk). Preferably said lipid acyltranferase is a polypeptide having lipid acyltransferase activity which polypeptide is obtained by expression of the nucleotide sequence shown as SEQ ID No. 49 or a nucleotide sequence which as has 70% or more identity therewith; and/or is obtained by expression of a nucleic acid which hybridises under medium stringency conditions to a nucleic probe comprising the nucleotide sequence shown as SEQ ID No. 49; and/or is a polypeptide having lipid acyltranferase activity which polypeptide comprises the amino acid sequence shown as SEQ ID No. 68 or an amino acid sequence which as has 70% or more identity therewith.